Even though the number of biomaterials products is expected to grow over the next four years, low reimbursement rates will limit sale prices. In 2011, the highest revenue-generating spine biologics product was Medtronic’s Infuse, which has faced challenges over the past six months from negative reports on its off-label use, according to the report. These reports are projected to have a negative impact on the market as a whole.
Competition in the biomaterials market continues to grow and some small companies are using merger and acquisition strategies with larger companies to combat economic challenges. The report also predicts an increased demand for premium-priced products that are seen as having more favorable properties, including second generation synthetics and stem cell products.
According to the report, the HA viscosupplementation market will show the strongest growth through 2016, driven by the 2012 launch of Seikagaku’s Gel-One and Anika Therapeutics’ Monovisc—two 1-injection products.
Related Articles on Orthopedic Devices:
Wright Medical Group Launches Foot and Ankle Systems
Synthes Takes on 3 Former Sales Reps, Stryker in Loyalties Case
Symmetry Medical Completes Acquisition of Surgical Implants Company
